**Supplemental Digital Content 3: Details about systemic therapy**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  | **Stage III (1)** | **Stage IV (1)** |  |  |  |  |
| **a) First systemic treatment received** | (n=31), [n (%)] |  (n=36), [n (%)] |  |  |   |  |
| ChT |  0 (0) | 17 (47.2) |  |   |   |  |
| IT |  9 (29) |  9 (25) |  |   |   |  |
| TT |  1 (3.2) |  3 (8.3) |  |   |   |  |
| None | 21 (67.7) |  6 (16.7) |  |   |   |  |
| Othera |  0 (0) |  1 (2.8) |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  | **Previous treatment: ChT** | **Previous treatment: IT** | **Previous treatment: TT** |
| **b) Second systemic treatment received** | (n=17) |   | (n=18) |   | (n=4) |   |
| ChT |  4  |  |  5  |   |  1  |  |
| IT |  4  |  |  4  |   |  2  |  |
| TT |  4  |  |  0  |   |  0 |  |
| None |  5  |  |  8  |  |  1  |  |
| Otherb |  0  |   |  1  |   |  0 |   |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **c) Third systemic treatment received** | (n=13) |   | **d) Fourth treatment received** | (n=5) |   |
| ChT |  6  |   | ChT |   |  1  |  |
| IT |  4  |   | IT |   |  1  |  |
| TT |  3 |   | TT |   |  3  |   |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **e) Fifth treatment received** | (n=3) |  | **f) Sixth treatment received** | (n=1) |   |
| ChT |  2  |   | ChT |  | 1 |  |
| IT |  0 |  | IT |  | 0 |  |
| TT |  1  |   | TT |   | 0 |   |

First treatment is listed separately for stage III and IV patients, all other treatments are referring to all patients with metastatic disease, regardless of stage. ChT, chemotherapy; IT, immunotherapy, TT, targeted therapy.

adacarbazine+adeno-IL-2 (chemo/immunotherapy); bpasireotide (somatostatin-analogon)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Sondak VK *et al.* Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* 2009; **27**:6199-206.